HER-2 negative breast cancer market to quadruple by 2023, says GlobalData

5 February 2015

The market value for therapeutics to treat HER2-negative breast cancer will increase more than fourfold between 2013 and 2023, says market research company GlobalData.

The company estimates it will increase from a value of $1.45 billion in 2013 to as much as $6.12 billion by 2023, as the treatment landscape moves away from chemotherapy to hormone therapies.

This growth is likely to occur primarily in the USA, France, Germany, Italy, Spain, the UK, Japan and China, and will be at a compound annual growth rate (CAGR) of 15.5%. The launch of several premium-priced products and their reimbursements are likely to drive this growth.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK